Broadly neutralizing antibodies against COVID-19.
Journal
Current opinion in virology
ISSN: 1879-6265
Titre abrégé: Curr Opin Virol
Pays: Netherlands
ID NLM: 101560941
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
10
02
2023
revised:
26
04
2023
accepted:
02
05
2023
medline:
8
8
2023
pubmed:
7
6
2023
entrez:
7
6
2023
Statut:
ppublish
Résumé
The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an effective treatment. Since SARS-CoV-2 emerged, a variety of strains have acquired increasing numbers of mutations to gain increased transmissibility and escape from the immune response. Most reported neutralizing human mAbs, including all approved therapeutic ones, have been knocked down or out by these mutations. Broadly neutralizing mAbs are therefore of great value, to treat current and possible future variants. Here, we review four types of neutralizing mAbs against the spike protein with broad potency against previously and currently circulating variants. These mAbs target the receptor-binding domain, the subdomain 1, the stem helix, or the fusion peptide. Understanding how these mAbs retain potency in the face of mutational change could guide future development of therapeutic antibodies and vaccines.
Identifiants
pubmed: 37285620
pii: S1879-6257(23)00032-9
doi: 10.1016/j.coviro.2023.101332
pmc: PMC10301462
pii:
doi:
Substances chimiques
Broadly Neutralizing Antibodies
0
Antibodies, Neutralizing
0
Antibodies, Monoclonal
0
Antibodies, Viral
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101332Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101122/Z/13/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N00065X/1
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Oxford University holds intellectual property related to SARS-CoV-2 mAbs discovered in Gavin R Screaton’s laboratory and DIS consults for AstraZeneca
Références
Cell Discov. 2022 Sep 8;8(1):87
pubmed: 36075908
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Sci Transl Med. 2022 May 25;14(646):eabn6859
pubmed: 35438546
Nat Commun. 2023 Jan 19;14(1):311
pubmed: 36658148
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Nat Commun. 2021 Mar 17;12(1):1715
pubmed: 33731724
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Nat Microbiol. 2022 Jul;7(7):1063-1074
pubmed: 35773398
Cell Host Microbe. 2022 Jan 12;30(1):53-68.e12
pubmed: 34921776
Nature. 2022 Apr;604(7906):546-552
pubmed: 35228716
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Science. 2022 Aug 12;377(6607):735-742
pubmed: 35857703
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Nature. 2022 Mar;603(7903):919-925
pubmed: 35090164
Sci Immunol. 2022 Oct 28;7(76):eadd5446
pubmed: 35951767
Cell Rep. 2022 Aug 23;40(8):111276
pubmed: 35981534
Sci Transl Med. 2022 Mar 23;14(637):eabi9215
pubmed: 35133175
Cell. 2021 Apr 29;184(9):2316-2331.e15
pubmed: 33773105
Cell Rep. 2022 May 17;39(7):110812
pubmed: 35568025
Sci Adv. 2022 Oct 7;8(40):eadd2032
pubmed: 36197988
Immunity. 2021 Jun 8;54(6):1276-1289.e6
pubmed: 33836142
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Cell. 2023 Jan 19;186(2):279-286.e8
pubmed: 36580913
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nature. 2022 Apr;604(7906):553-556
pubmed: 35240676
Nature. 2021 Sep;597(7874):97-102
pubmed: 34261126
Cell Rep. 2022 Jan 11;38(2):110210
pubmed: 34971573
Commun Biol. 2022 Apr 11;5(1):342
pubmed: 35411021
Nat Commun. 2021 Jan 12;12(1):288
pubmed: 33436577
J Virol. 2009 Aug;83(15):7411-21
pubmed: 19439480
Cell Host Microbe. 2022 Aug 10;30(8):1077-1083.e4
pubmed: 35594867
Signal Transduct Target Ther. 2023 Jul 31;8(1):281
pubmed: 37518189
Immunity. 2022 Aug 9;55(8):1501-1514.e3
pubmed: 35777362
Science. 2021 Sep 03;373(6559):1109-1116
pubmed: 34344823
Sci Immunol. 2023 Mar 17;8(81):eade0958
pubmed: 36701425
Science. 2022 Aug 12;377(6607):728-735
pubmed: 35857439
Nat Commun. 2023 Apr 17;14(1):2179
pubmed: 37069158
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nat Struct Mol Biol. 2020 Oct;27(10):950-958
pubmed: 32737466
Science. 2021 Oct 22;374(6566):472-478
pubmed: 34554826
Cell. 2022 Jun 9;185(12):2116-2131.e18
pubmed: 35662412
Nat Struct Mol Biol. 2021 Jun;28(6):478-486
pubmed: 33981021
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Nat Commun. 2022 Aug 24;13(1):4958
pubmed: 36002453
Protein Cell. 2022 Sep;13(9):655-675
pubmed: 34554412
J Biomed Sci. 2022 Sep 12;29(1):68
pubmed: 36096815
Emerg Microbes Infect. 2022 Dec;11(1):351-367
pubmed: 34964428
Structure. 2021 Jul 1;29(7):655-663.e4
pubmed: 34111408
Cell Discov. 2023 Jan 7;9(1):3
pubmed: 36609558
Nat Commun. 2022 Jun 13;13(1):3375
pubmed: 35697673
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Cell Rep. 2023 Apr 25;42(4):112271
pubmed: 36995936
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651